Home > Focus Areas > Retina Health Connect > Post
Time course of changes in vision-related quality of life following intravitreal ranibizumab treatment for branch retinal vein occlusion - Scientific Reports
Source : https://www.nature.com/articles/s41598-022-17587-0
To evaluate the vision-related quality of life (VR-QOL) treated by intravitreal ranibizumab (IVR) in patients with branch retinal vein occlusion (BRVO) and to assess subscale items of the VR-QOL. This was prospective, multicenter, open-label, observational study including 38 patients with unilateral BRVO who underwent IVR treatment and 28 age-matched healthy subjects.
Relevance: To evaluate the vision-related quality of life (VR-QOL) treated by intravitreal ranibizumab (IVR) in patients with branch retinal vein occlusion (BRVO) and to assess subscale items of the VR-QOL.